GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gyre Therapeutics Inc (NAS:GYRE) » Definitions » Net Issuance of Debt

GYRE (Gyre Therapeutics) Net Issuance of Debt : $0.00 Mil (TTM As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Gyre Therapeutics Net Issuance of Debt?

Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive. Gyre Therapeutics's net issuance of debt for the three months ended in Jun. 2024 was $0.00 Mil. Its net issuance of debt for the trailing twelve months (TTM) ended in Jun. 2024 was $0.00 Mil.

Gyre Therapeutics Net Issuance of Debt Historical Data

The historical data trend for Gyre Therapeutics's Net Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gyre Therapeutics Net Issuance of Debt Chart

Gyre Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Net Issuance of Debt
-6.70 -0.47 -

Gyre Therapeutics Quarterly Data
Dec21 Mar22 Dec22 Mar23 Jun23 Dec23 Mar24 Jun24
Net Issuance of Debt Get a 7-Day Free Trial - - - - -

Gyre Therapeutics Net Issuance of Debt Calculation

This is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Net Issuance of Debt for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gyre Therapeutics Net Issuance of Debt Related Terms

Thank you for viewing the detailed overview of Gyre Therapeutics's Net Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Gyre Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gyre Therapeutics Inc (NAS:GYRE) » Definitions » Net Issuance of Debt
Comparable Companies
Traded in Other Exchanges
L9S:Germany
Address
12770 High Bluff Drive, Suite 150, San Diego, CA, USA, 92130
Website
https://www.gyretx.com
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.